Q2 2024 EPS Estimates for Bruker Co. (NASDAQ:BRKR) Decreased by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Bruker in a research report issued to clients and investors on Thursday, May 2nd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.54 per share for the quarter, down from their prior forecast of $0.59. The consensus estimate for Bruker’s current full-year earnings is $2.82 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2024 earnings at $0.78 EPS, Q4 2024 earnings at $0.98 EPS, FY2024 earnings at $2.83 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.72 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $1.20 EPS and FY2026 earnings at $4.02 EPS.

Several other research analysts have also issued reports on BRKR. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and raised their target price for the company from $60.00 to $90.00 in a research note on Wednesday, February 14th. Stifel Nicolaus increased their price objective on Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, February 14th. UBS Group boosted their target price on shares of Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a report on Friday, March 1st. Citigroup increased their price target on shares of Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Finally, The Goldman Sachs Group lifted their price target on shares of Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $84.86.

Bruker Stock Performance

Shares of BRKR opened at $74.33 on Monday. The company has a 50-day simple moving average of $86.98 and a two-hundred day simple moving average of $75.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The firm has a market capitalization of $10.80 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 1.73 and a beta of 1.22. Bruker has a one year low of $53.79 and a one year high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. The business had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 EPS.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, February 29th. Bruker’s dividend payout ratio (DPR) is 7.27%.

Insider Buying and Selling at Bruker

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $90.06, for a total value of $1,350,900.00. Following the transaction, the director now owns 23,147 shares in the company, valued at $2,084,618.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. 28.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

A number of institutional investors have recently made changes to their positions in the stock. Inspire Advisors LLC bought a new position in Bruker during the first quarter valued at approximately $271,000. Sfmg LLC purchased a new stake in Bruker during the 1st quarter valued at $202,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Bruker in the first quarter worth $761,000. Oppenheimer Asset Management Inc. increased its position in Bruker by 16.4% during the first quarter. Oppenheimer Asset Management Inc. now owns 20,659 shares of the medical research company’s stock valued at $1,941,000 after acquiring an additional 2,918 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its position in Bruker by 3.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,606 shares of the medical research company’s stock worth $1,278,000 after purchasing an additional 432 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.